Parathyroid scintigraphy: Comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies

European Journal of Nuclear Medicine

Volumn 23, Issue 6, 1996, Pages 693-696

  Aigner, R M ^a,b   Fueger, G F ^a   Nicoletti, R ^a  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Hyperparathyroidism; Parathyroid adenoma; Technetium 99m 1,2 bis(bis(2 ethoxyethyl)phosphino)ethane; Technetium 99m methoxyisobutylisonitrile

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; TETROFOSMIN TC 99M; TRACER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMAGING; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; NUCLEAR MEDICINE; PARATHYROID ADENOMA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID SCINTISCANNING;

ADENOMA; AGED; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PARATHYROID NEOPLASMS; PROSPECTIVE STUDIES; TECHNETIUM TC 99M SESTAMIBI;

EID: 0029974350     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00834533     Document Type: Article

References (10)

1. Casara D, Rubello D, Saladini G, etal. Clinical role of Tc-99m-MIBI scintigraphy in parathyroid imaging, a comparative study with TI-201 seintigraphy, echography and CT. Eur J Nucl Med 1991; 18: 531.
2. Kelley JD, Forster AM, Higley B, etal. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993; 34: 222-227.
3. Civelek AC, Durski K, Shafique I, etal. Failure of perchlorate to inhibit Tc-99m-isonitrile binding by the thyroid during myocardial perfusion studies. Clin Nucl Med 1991; 16: 358-361.
4. Piwicna-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
5. Sandrock D, Merino MJ, Norton JA, Neumann RD. Ultrastructural histology correlates with results of thallium-201/technetium-99m parathyroid substration scintigraphy. J Nucl Med 1993; 34: 24-29.
6. Wackers FJ, Berman DJ, Maddahi J, Watson DD, Beller GA, Strauss HW, Boucher CA, Picard M, Holman BL, Fridrich R, Inglese E, Delaloye B, Bischof-Delaloye A, Camin L, McKusik K. Technetium-99m-hexakis-2-methoxyisobutylisonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30: 301-311.
7. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med 1992; 33: 1801-1807.
8. O'Doherty JO, Kettle AG, Wells P, etal. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med 1992; 33: 313.
9. Osmanagaoglu K, Schelstraete K, Lippens M, Obrie E, De Feyter I. Visualization of a parathyroid adenoma with Tc-99m MIBI in a case with iodine saturation and impaired tallium uptake. Clin Nucl Med 1993; 18: 214-216.
10. Higley B, Smith FW, Smith T, Gemmell HG, etal. Technetium-99m-1,2bis(bis(2-ethoxy-ethyl)phosphino)ethane: human biodistribution, dosimetry, and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30-38.